Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor
Immune checkpoint inhibitors have shown anti-tumour activity in cancers such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma, colorectal cancer, and Hodgkin’s lymphoma. Though immune checkpoint inhibitors have revolutionized the treatment and prognosis of some adv...
Main Authors: | Marta Rocha, João Correia de Sousa, Marta Salgado, António Araújo, Isabel Pedroto |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2018-12-01
|
Series: | GE: Portuguese Journal of Gastroenterology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/494569 |
Similar Items
-
Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
by: Johnny Chahine, MD, et al.
Published: (2020-02-01) -
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
by: I. Puzanov, et al.
Published: (2017-11-01) -
Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
by: Marina A. Lyadova, et al.
Published: (2021-08-01) -
Overview and management of toxicities of immune checkpoint-blocking drugs
by: Economopoulou Panagiota, et al.
Published: (2016-03-01) -
IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)